Revenue Update on Parnell Pharmaceuticals Holdings Ltd(NASDAQ:PARN)

Parnell Pharmaceuticals Holdings Ltd(NASDAQ:PARN) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Mar 21, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.12.

Parnell Pharmaceuticals Holdings Ltd. is a veterinary pharmaceutical company. The Company is focused on developing manufacturing and commercializing health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product and research and development of pharmaceutical products for global animal health markets. It operates in four segments: Companion Animal which covers its Osteoarthritis portfolios across both Canine and Equine species; Production Animal-U.S. which covers its Reproductive Hormone portfolio across Production Animal in the United States of America; Production Animal-Rest of World which covers the its reproductive hormone portfolio in Production Animal across all regions outside of the United States of America and Manufacturing Operations is responsible for the operation its Food and Drug Administration approved sterile manufacturing facility and the manufacture and release of all its pharmaceutical products.

Add Comment